Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenues from Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three months ended March 31, 2016 and 2015:

	Three Months Ended March 31,
	2016		2015
Teva:
Recognition of upfront payment		—		2,876
Research funding		29		45
Genentech:
Recognition of upfront payment		157		179
Research funding		383		910
Total collaboration revenue	$	569	$	4,010